Multiplicity and history have a detrimental effect on survival of patients with T1G3 bladder tumors selected for conservative treatment

被引:8
|
作者
Serretta, Vincenzo [1 ,2 ]
Ruggirello, Antonina [1 ,2 ]
Dispensa, Nino [1 ,2 ]
Allegro, Rosalinda [2 ,4 ]
Aragona, Federico [3 ]
Melloni, Darvinio [1 ]
机构
[1] Univ Palermo, Dept Internal Med, Urol Sect, Palermo, Italy
[2] Univ Palermo, Dept Cardiovasc & Nephrourol Dis, Urol Sect, Palermo, Italy
[3] Univ Palermo, Dept Human Pathol, Palermo, Italy
[4] Grp Tumori Urol Fdn, Dept Stat, Palermo, Italy
关键词
carcinoma; transitional cell; survival; chemotherapy; adjuvant; neoplasms; multiple primary; recurrence;
D O I
10.1016/j.juro.2008.05.013
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Purpose: In the absence of Tis tumor we assessed whether history and multiplicity have a detrimental effect on conservative treatment in carefully selected patients with T1G3 bladder carcinoma. Materials and Methods: Between January 1976 and December 1999, 165 select patients with T1G3 bladder tumors were conservatively treated with transurethral resection plus adjuvant intravesical therapy. Patients with concomitant or previous Tis, previous T1G3, tumor size greater than 3 cm and more than 3 lesions were excluded from analysis. Repeat transurethral resection was not routinely performed. However, cytology had to be negative for atypia before the start of adjuvant intravesical therapy. Results: Recurrence-free survival at 1, 3 and 5 years was 71.8%, 55.6% and 45%, respectively. Of the cases 14 (8.4%) progressed with a median progression-free survival of 149 months. A total of 23 patients (14%) died. The 5-year recurrence-free survival rate was 52%, 34% and 15% in cases of single and/or primary, multiple and recurrent tumors, respectively. Median overall survival was 144 months. The 5-year disease-free overall survival rate was 85%, 83%, 79% and 69% in cases of primary, single, multiple and recurrent tumors, respectively. An intact bladder was maintained in 137 patients (83%) with a mean disease-free overall survival of 102.7 months. Patients with recurrent and/or multiple T1G3 tumors showed worse survival (p = 0.0021 and 0.0142, respectively). Conclusions: History and multiplicity are relevant predictors of survival even in highly selected patients with T1G3 bladder tumors that are conservatively treated.
引用
收藏
页码:886 / 890
页数:5
相关论文
共 50 条
  • [1] Intravesical bacillus Calmette-Guerin treatment improves patient survival in T1G3 bladder tumours
    Patard, JJ
    Rodriguez, A
    Leray, E
    Rioux-Leclercq, N
    Guillé, F
    Lobel, B
    EUROPEAN UROLOGY, 2002, 41 (06) : 635 - 641
  • [2] Conservative management and survival of patients affected by T1G3 bladder tumours. When shall we indicate it and when the cystectomy?
    Ruggirello, A.
    Serretta, V.
    Passalacqua, D.
    Zaccone, V.
    Daricello, M.
    Aragona, F.
    Allegro, R.
    Melloni, D.
    UROLOGIA JOURNAL, 2009, 76 : S31 - S35
  • [3] T1G3 transitional cell carcinoma of the bladder: recurrence, progression and survival
    Peyromaure, M
    Zerbib, M
    BJU INTERNATIONAL, 2004, 93 (01) : 60 - 63
  • [4] Prognostic significance of non-papillary tumor morphology as a predictor of cancer progression and survival in patients with primary T1G3 bladder cancer
    Park, Jinsung
    Song, Cheryn
    Hong, Jun Hyuk
    Park, Bong-Hee
    Cho, Yong Mee
    Kim, Choung-Soo
    Ahn, Hanjong
    WORLD JOURNAL OF UROLOGY, 2009, 27 (02) : 277 - 283
  • [5] Tumor Multiplicity is an Independent Prognostic Factor of Non-muscle-invasive High-grade (T1G3) Bladder Cancer
    Nakai, Yasutomo
    Nonomura, Norio
    Kawashima, Atsunari
    Mukai, Masatoshi
    Nagahara, Akira
    Nakayama, Masashi
    Takayama, Hitoshi
    Nishimura, Kazuo
    Okuyama, Akihiko
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2010, 40 (03) : 252 - 257
  • [6] Photodynamic diagnosis in patients with T1G3 bladder cancer: influence on recurrence rate
    Stanislaus, Peter
    Zaak, Dirk
    Stadler, Thomas
    Tritschler, Stefan
    Knuechel, Ruth
    Stief, Christian G.
    Karl, Alexander
    WORLD JOURNAL OF UROLOGY, 2010, 28 (04) : 407 - 411
  • [7] 15-year experience on intravesical therapy of T1G3 urinary bladder cancer: a conservative approach
    Cheng, CW
    Chan, SFP
    Chan, LW
    Chan, CK
    Ng, CF
    Cheung, HY
    Chan, SYE
    Wong, WS
    Lai, FMM
    Li, ML
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2004, 34 (04) : 202 - 205
  • [8] Primary T1G3 bladder cancer: Organ preserving approach or immediate cystectomy?
    Thalmann, GN
    Markwalder, R
    Shahin, O
    Burkhard, FC
    Hochreiter, WW
    Studer, UE
    JOURNAL OF UROLOGY, 2004, 172 (01) : 70 - 75
  • [9] T1G3 superficial bladder tumor: about 24 cases
    Benchekroun, A
    El Alj, HA
    El Sayegh, H
    Lachkar, A
    Nouini, Y
    Benslimane, L
    Belahnech, Z
    Faik, M
    ANNALES D UROLOGIE, 2003, 37 (04) : 199 - 202
  • [10] Prediction of recurrence and progression in patients with T1G3 bladder cancer by gene expression of circulating tumor cells
    Awadalla, Amira
    Abol-Enein, H.
    Gabr, Mahmoud M.
    Hamam, Eman T.
    Shokeir, Ahmed A.
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2020, 38 (04) : 278 - 285